Facile approach for the synthesis of rivaroxaban using alternate synthon: reaction, crystallization and isolation in single pot to achieve desired yield, quality and crystal form
Tóm tắt
An efficient and high yielding process for the production of impurity free rivaroxaban (1), an anti-coagulant agent using alternate synthon is reported. The key components of the process involve; synthesis of 4-(4-aminophenyl)-3-morpholinone (5) using easily available inexpensive nitro aniline (17), condensation of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride (9) with alternate synthon 4-nitrophenyl 5-chlorothiophene-2-carboxylate (11) in dimethylsulfoxide (DMSO) as a solvent and triethylamine as a base and isolation of the rivaroxaban (1) by designing the crystallization in same reaction pot using specific combination of acetonitrile and methanol as anti-solvents to obtain highly pure rivaroxaban (1) with desired ploymorphic form with an overall yield of around 22% (Calculated from 17). The developed process avoids the use of hazardous chemicals, critical operations and tedious work-ups. Potential impurities arouse during the reaction at various stages and carry-over impurities from starting materials were controlled selectively by designing reaction conditions and tuning the crystallization parameters.
Tài liệu tham khảo
Drug index. Xarelto (Rivaroxaban film coated oral tablet); Drug information, desription, user reviews, drug side effects, interactions—prescribing information at Rx List. http://www.rxlist.com/xarelto-drug.htm. Accessed June 2015
Highlights of prescribing information of XARELTO, rivaroxaban, Extended-Release tablets. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf. Accessed 2011
Susanne R, Alexander S, Jens P, Thomas L, Josef P, Karl-Heinz S et al (2005) Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 48:5900–5908
Alexander S, Thomas L, Jens P, Susanne R, Elisabeth P et al (2009) Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation. U.S. Patent 7,576,111
Rafecas JL, Comely AC, Ferrali A, Amelacortes C, Pasto AM (2011) Process for the preparation of rivaroxaban and intermediates thereof. PCT Int Appl WO2011080341 A1
Silvo Z, Anica P (2011) Processes for crystallization of rivaroxaban. PCT Int Appl WO2011012321 A1
Sturm H, Desouza D, Knepper K, Alert M (2011) Method for the preparation of rivaroxaban. PCT Int Appl WO2011098501 A1
Bodhauri P, Weeratunga G (2012) Processes for the preparation of rivaroxaban and intermediates thereof. PCT Int Appl WO2012051692 A1
Eva S, Gyorgyi KL, Balazs H, Balazs V, Gyorgy K, Gyorgy R et al (2012) Process for the preparation of a rivaroxaban and intermediates formed in said process. PCT Int Appl WO2012153155 A1
Rodriguez B, Olondriz M, Soldevilla L, Comas S (2012) Process for obtaining rivaroxaban and intermediate thereof. PCT Int Appl WO2012159992 A1
Singh PK, Hashmi MS, Sachdeva YP, Khanduri CH (2013) Process for the preparation of rivaroxaban and intermediates thereof. PCT Int Appl WO2013156936 A1
Halama A, Krulis R, Brichac J (2013) A process for the preparation of rivaroxaban based on saving of 1, 1′-carbonyl diimidazole. PCT Int Appl WO2013120464 A1
Dwivedi SD, Prasad A, Pal DR, Sharma MHP, Jain KN, Patel NB (2013) Processes and intermediates for preparing rivaroxaban. PCT Int Appl WO2013098833 A2
Rao MD, Reddy VB (2013) Improved process for preparing rivaroxaban using novel intermediates. PCT Int Appl WO2013164833 A1
Rao MD, Reddy VB (2013) A process for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene carboxamide. PCT Int Appl WO2013118130 A1
Keshav SP, Bhise SS, Kamble HH, Chaudhari G, Patil DS (2014) Process for the preparation of rivaroxaban. PCT Int Appl WO2014155259 A2
Pradhan NS, Patil NS, Walavalkar RR, Kulkarni NS, Pawar SB, Pawar TS (2014) Rivaroxaban intermediate and preparation thereof. PCT Int Appl WO2014102820 A2
Silvo Z, Primoz B (2014) A process for preparation of rivaroxaban. PCT Int Appl WO2014096214 A1
Pradhan NS, Patil NS, Walavalkar RR, Kulkarni NS, Pawar SB, Pawar TS (2014) Aldehyde derivative of substitute oxazolidinones. PCT Int Appl WO2014102822 A2
ICH Harmonized Tripartite Guideline. Impurities: guideline for residual solvents, Q3C (R5). http://www.ich.org/products/guidelines/quality/quality-single/article/impurities-guidline-for-residual-solvents.html. Accessed 3 Jan 2013
Grunenburg A, Lenz J, Braun GA, Keil B, Thomas CR (2010) Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo-3[4-(3-oxo-4-morpholinyl(-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide. US Patent 20100152189 A1
Mathad VT (2013) Crystallization: theory and/vs. practice—few case studies’, a presentation made in Crystallization-2013, held on 16–17 April 2013 by UBM/CPHI-India at Mumbai, India
Mathad VT, Joshi DR, Lad HD, Patel PI (2012) A process for production of 4-(4-aminophenyl)-3-morpholinone. IN patent 3478/MUM/2012
ACS GCI Pharmaceutical Roundtable. Green Chemistry Reporting Requirements for an Electronic Laboratory Notebook (ELN); http://portal.acs.org/portal/PublicWebsite/greenchemistry/industriainnovation/roundtable/CNBP_026687. Accessed 2011